Synonyms: BGB-283 | compound 2.2b [2]
Compound class:
Synthetic organic
Comment: Lifirafenib (BGB-283) is an investigational inhibitor of the Raf kinases (ARAF, BRAF, CRAF) and the epidermal growth factor receptor (EGFR) tyrosine kinase [1]. BGB-283 is being investigated for its antineoplastic activity. The compound is one of the structures described in patent WO2013097224 A1 [2].
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use |
BGB-283 is being evaluated in Phase 1 clinical trial for its potential to treat solid tumours (see NCT02610361). |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT02610361 | Study of the Safety and Pharmacokinetics of BGB-283 in Patients With Solid Tumors | Phase 1 Interventional | BeiGene |